[{"id":"1788e76b-7d7b-4891-bdd0-dfbb58176132","acronym":"","url":"https://clinicaltrials.gov/study/NCT07046078","created_at":"2025-07-05T13:57:24.531Z","updated_at":"2025-07-05T13:57:24.531Z","phase":"Phase 2","brief_title":"Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer","source_id_and_acronym":"NCT07046078","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" CD33","pipe":"","alterations":" ","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • idarubicin hydrochloride • fludarabine IV • Starasid (cytarabine ocfosfate)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 07/01/2025","start_date":" 07/01/2025","primary_txt":" Primary completion: 06/30/2027","primary_completion_date":" 06/30/2027","study_txt":" Completion: 06/30/2029","study_completion_date":" 06/30/2029","last_update_posted":"2025-07-02"},{"id":"b813594c-e262-462c-9ebd-af975b8871b2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04375631","created_at":"2021-01-18T21:08:17.296Z","updated_at":"2025-02-25T13:53:16.560Z","phase":"Phase 1","brief_title":"CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia","source_id_and_acronym":"NCT04375631","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • cyclophosphamide • idarubicin hydrochloride • mitoxantrone • cladribine • fludarabine IV • cyclosporin A microemulsion • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 12/03/2020","start_date":" 12/03/2020","primary_txt":" Primary completion: 02/28/2027","primary_completion_date":" 02/28/2027","study_txt":" Completion: 03/17/2027","study_completion_date":" 03/17/2027","last_update_posted":"2025-02-20"},{"id":"2215a379-2b74-4e43-b073-534f2995d428","acronym":"","url":"https://clinicaltrials.gov/study/NCT06001788","created_at":"2023-08-21T14:08:48.344Z","updated_at":"2025-02-25T15:13:42.778Z","phase":"Phase 1","brief_title":"Safety and Tolerability of Ziftomenib Combinations in Patients with Relapsed/Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT06001788","lead_sponsor":"Kura Oncology, Inc.","biomarkers":" FLT3 • NPM1 • KMT2A","pipe":" | ","alterations":" FLT3 mutation • NPM1 mutation • KMT2A rearrangement • KMT2A mutation • MLL mutation","tags":["FLT3 • NPM1 • KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • NPM1 mutation • KMT2A rearrangement • KMT2A mutation • MLL mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Xospata (gilteritinib) • idarubicin hydrochloride • Komzifti (ziftomenib) • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 171","initiation":"Initiation: 02/22/2024","start_date":" 02/22/2024","primary_txt":" Primary completion: 08/01/2026","primary_completion_date":" 08/01/2026","study_txt":" Completion: 08/01/2027","study_completion_date":" 08/01/2027","last_update_posted":"2025-02-13"},{"id":"1b4e994d-52e1-4f2a-9230-cf391cb47aea","acronym":"NCI-2023-03572","url":"https://clinicaltrials.gov/study/NCT06034470","created_at":"2023-09-13T14:09:48.343Z","updated_at":"2025-02-25T17:02:50.246Z","phase":"Phase 1","brief_title":"Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms","source_id_and_acronym":"NCT06034470 - NCI-2023-03572","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" IL3RA","pipe":" | ","alterations":" Chr t(15;17)","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(15;17)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • idarubicin hydrochloride • fludarabine IV • pivekimab sunirine (PVEK) • Starasid (cytarabine ocfosfate)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 12/18/2023","start_date":" 12/18/2023","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-03"},{"id":"5ba9d628-6d23-4d5d-9027-4c4a55c8330e","acronym":"NCI-2019-08626","url":"https://clinicaltrials.gov/study/NCT04214249","created_at":"2024-01-11T17:17:48.143Z","updated_at":"2025-02-25T17:00:21.915Z","phase":"Phase 2","brief_title":"BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia","source_id_and_acronym":"NCT04214249 - NCI-2019-08626","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • TMB • CD8 • PD-1 • CD47 • GZMB • FOXP3","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • TMB • CD8 • PD-1 • CD47 • GZMB • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cytarabine • daunorubicin • idarubicin hydrochloride • Starasid (cytarabine ocfosfate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 02/17/2021","start_date":" 02/17/2021","primary_txt":" Primary completion: 11/27/2024","primary_completion_date":" 11/27/2024","study_txt":" Completion: 01/30/2026","study_completion_date":" 01/30/2026","last_update_posted":"2025-02-03"},{"id":"8e4c392a-1d29-432d-a4da-6bb8e1258676","acronym":"AG120-221-C-001","url":"https://clinicaltrials.gov/study/NCT02632708","created_at":"2021-01-17T17:12:58.212Z","updated_at":"2025-02-25T14:36:02.501Z","phase":"Phase 1","brief_title":"Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation","source_id_and_acronym":"NCT02632708 - AG120-221-C-001","lead_sponsor":"Institut de Recherches Internationales Servier","biomarkers":" IDH1 • IDH2 • UGT1A1","pipe":" | ","alterations":" IDH2 mutation • UGT1A1*1*1 • Chr t(15;17) • UGT1A1 mutation","tags":["IDH1 • IDH2 • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • UGT1A1*1*1 • Chr t(15;17) • UGT1A1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • etoposide IV • Tibsovo (ivosidenib) • daunorubicin • Idhifa (enasidenib) • idarubicin hydrochloride • mitoxantrone"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 153","initiation":"Initiation: 12/31/2015","start_date":" 12/31/2015","primary_txt":" Primary completion: 12/13/2018","primary_completion_date":" 12/13/2018","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-07-25"},{"id":"3d3f57b8-7c54-40f3-80db-21c1598bb35e","acronym":"","url":"https://clinicaltrials.gov/study/NCT02310321","created_at":"2021-01-18T10:56:18.517Z","updated_at":"2024-07-02T16:34:37.261Z","phase":"Phase 1/2","brief_title":"A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia.","source_id_and_acronym":"NCT02310321","lead_sponsor":"Astellas Pharma Inc","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Xospata (gilteritinib) • idarubicin hydrochloride"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 84","initiation":"Initiation: 02/26/2015","start_date":" 02/26/2015","primary_txt":" Primary completion: 08/25/2021","primary_completion_date":" 08/25/2021","study_txt":" Completion: 07/31/2024","study_completion_date":" 07/31/2024","last_update_posted":"2024-06-07"},{"id":"4dcb8f8b-2695-4bef-a128-38e8217912be","acronym":"","url":"https://clinicaltrials.gov/study/NCT05177731","created_at":"2022-01-05T13:53:46.126Z","updated_at":"2024-07-02T16:34:36.990Z","phase":"Phase 3","brief_title":"Venetoclax + Decitabine vs. \"7+3\" Induction Chemotherapy in Young AML","source_id_and_acronym":"NCT05177731","lead_sponsor":"Chen Suning","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • Xospata (gilteritinib) • decitabine • idarubicin hydrochloride"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 188","initiation":"Initiation: 03/01/2022","start_date":" 03/01/2022","primary_txt":" Primary completion: 02/28/2024","primary_completion_date":" 02/28/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-06-07"},{"id":"7b7c91a6-9486-4633-b3e2-ffef9fa008f4","acronym":"ADMIRAL","url":"https://clinicaltrials.gov/study/NCT02421939","created_at":"2021-01-17T17:23:13.438Z","updated_at":"2024-07-02T16:35:01.814Z","phase":"Phase 3","brief_title":"A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation","source_id_and_acronym":"NCT02421939 - ADMIRAL","lead_sponsor":"Astellas Pharma Global Development, Inc.","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation • FLT3 mutation • FLT3 D835 • FLT3 I836","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • FLT3 mutation • FLT3 D835 • FLT3 I836"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Xospata (gilteritinib) • azacitidine • etoposide IV • idarubicin hydrochloride • mitoxantrone • fludarabine IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 371","initiation":"Initiation: 10/20/2015","start_date":" 10/20/2015","primary_txt":" Primary completion: 09/17/2018","primary_completion_date":" 09/17/2018","study_txt":" Completion: 07/31/2024","study_completion_date":" 07/31/2024","last_update_posted":"2024-05-23"},{"id":"fb6439e5-b767-47e6-9fe0-4ee26349fda0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05453903","created_at":"2022-07-12T10:54:42.198Z","updated_at":"2024-07-02T16:35:01.650Z","phase":"Phase 1","brief_title":"A Study of JNJ-75276617 in Combination With Acute Myeloid Leukemia (AML) Directed Therapies","source_id_and_acronym":"NCT05453903","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" NPM1 • KMT2A","pipe":"","alterations":" ","tags":["NPM1 • KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • azacitidine • daunorubicin • idarubicin hydrochloride • bleximenib (JNJ-6617)"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 10/04/2022","start_date":" 10/04/2022","primary_txt":" Primary completion: 05/15/2024","primary_completion_date":" 05/15/2024","study_txt":" Completion: 03/05/2026","study_completion_date":" 03/05/2026","last_update_posted":"2024-05-23"},{"id":"6176da79-a3c0-4b9a-9c46-e06b067b1a58","acronym":"V-FIRST","url":"https://clinicaltrials.gov/study/NCT03455504","created_at":"2021-01-18T17:02:14.792Z","updated_at":"2024-07-02T16:35:10.462Z","phase":"Phase 2","brief_title":"Venetoclax Add in Combination With Fludarabine, Cyratabine and Idarubicine in Induction for Acute Myelid Leukemia","source_id_and_acronym":"NCT03455504 - V-FIRST","lead_sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • idarubicin hydrochloride • fludarabine IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 124","initiation":"Initiation: 10/26/2018","start_date":" 10/26/2018","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-04-10"},{"id":"29adfbf7-ec59-401a-b21b-e4307b0a528a","acronym":"","url":"https://clinicaltrials.gov/study/NCT03591510","created_at":"2021-01-18T17:39:51.327Z","updated_at":"2024-07-02T16:35:11.198Z","phase":"Phase 2","brief_title":"A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML","source_id_and_acronym":"NCT03591510","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3 mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • etoposide IV • midostaurin • daunorubicin • idarubicin hydrochloride • mitoxantrone • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 03/13/2019","start_date":" 03/13/2019","primary_txt":" Primary completion: 08/18/2025","primary_completion_date":" 08/18/2025","study_txt":" Completion: 02/15/2029","study_completion_date":" 02/15/2029","last_update_posted":"2024-04-05"},{"id":"e90cec53-ae6c-493e-9af7-3f156a05c47e","acronym":"","url":"https://clinicaltrials.gov/study/NCT02400281","created_at":"2021-01-18T11:27:08.882Z","updated_at":"2024-07-02T16:35:13.589Z","phase":"Phase 1/2","brief_title":"Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients","source_id_and_acronym":"NCT02400281","lead_sponsor":"Arog Pharmaceuticals, Inc.","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3 mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • azacitidine • etoposide IV • crenolanib (ARO-002) • idarubicin hydrochloride • mitoxantrone • fludarabine IV"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 09/01/2015","start_date":" 09/01/2015","primary_txt":" Primary completion: 07/15/2020","primary_completion_date":" 07/15/2020","study_txt":" Completion: 07/15/2020","study_completion_date":" 07/15/2020","last_update_posted":"2024-03-20"},{"id":"4b7d8253-b538-4d01-afbf-759acf0e19ab","acronym":"","url":"https://clinicaltrials.gov/study/NCT04801797","created_at":"2021-03-17T16:56:59.748Z","updated_at":"2024-07-02T16:35:14.237Z","phase":"Phase 2","brief_title":"Venetoclax + Azacitidine vs. Induction Chemotherapy in AML","source_id_and_acronym":"NCT04801797","lead_sponsor":"Massachusetts General Hospital","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • Vyxeos (cytarabine/daunorubicin liposomal formulation) • idarubicin hydrochloride"],"overall_status":"Recruiting","enrollment":" Enrollment 172","initiation":"Initiation: 05/20/2021","start_date":" 05/20/2021","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2024-03-18"},{"id":"92f3f7c6-e282-4c02-a649-a3d88aca09fb","acronym":"","url":"https://clinicaltrials.gov/study/NCT04953780","created_at":"2024-03-18T13:21:29.779Z","updated_at":"2024-07-02T16:35:14.325Z","phase":"Phase 1","brief_title":"2157GCCC:Phase 1 of Calaspargase Pegol-mknl w/ Cytarabine and Idarubicin in Newly Dx AML","source_id_and_acronym":"NCT04953780","lead_sponsor":"University of Maryland, Baltimore","biomarkers":" MCL1 • BCL2L1","pipe":" | ","alterations":" BCL2 expression","tags":["MCL1 • BCL2L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • idarubicin hydrochloride • Asparlas (calaspargase pegol-mknl)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 09/27/2021","start_date":" 09/27/2021","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-03-18"},{"id":"6d194b66-a36a-4049-9be1-f272a6096889","acronym":"","url":"https://clinicaltrials.gov/study/NCT03117751","created_at":"2021-01-18T15:21:39.440Z","updated_at":"2024-07-02T16:35:16.300Z","phase":"Phase 2/3","brief_title":"Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma","source_id_and_acronym":"NCT03117751","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" BCL2 • CEP72","pipe":"","alterations":" ","tags":["BCL2 • CEP72"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • cytarabine • bortezomib • doxorubicin hydrochloride • Jakafi (ruxolitinib) • cyclophosphamide • Blincyto (blinatumomab) • etoposide IV • methotrexate • vincristine • prednisone • daunorubicin • Zolinza (vorinostat) • clofarabine • idarubicin hydrochloride • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • nelarabine • Asparlas (calaspargase pegol-mknl) • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • thioguanine • Erwinase (erwinia asparaginase) • Purixan (mercaptopurine oral suspension) • cyclophosphamide intravenous • prednisolone"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 790","initiation":"Initiation: 03/29/2017","start_date":" 03/29/2017","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 03/31/2028","study_completion_date":" 03/31/2028","last_update_posted":"2024-03-05"},{"id":"e5940e7b-30fd-4553-89ee-3676c7d30b8b","acronym":"A2408","url":"https://clinicaltrials.gov/study/NCT03379727","created_at":"2021-01-17T17:21:47.746Z","updated_at":"2024-07-02T16:35:17.043Z","phase":"Phase 3","brief_title":"Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Maintenance Monotherapy in Patients With Newly-diagnosed FMS-like Tyrosine 3 (FLT3) Kinase Receptor-mutated Acute Myeloid Leukemia.","source_id_and_acronym":"NCT03379727 - A2408","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3 mutation • Chr t(15;17)","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • Chr t(15;17)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • midostaurin • daunorubicin • idarubicin hydrochloride"],"overall_status":"Completed","enrollment":" Enrollment 301","initiation":"Initiation: 02/13/2018","start_date":" 02/13/2018","primary_txt":" Primary completion: 07/09/2021","primary_completion_date":" 07/09/2021","study_txt":" Completion: 07/09/2021","study_completion_date":" 07/09/2021","last_update_posted":"2024-02-29"},{"id":"d089607a-1031-4001-af05-f61c61e55845","acronym":"","url":"https://clinicaltrials.gov/study/NCT02013648","created_at":"2021-01-18T09:12:24.696Z","updated_at":"2024-07-02T16:35:17.930Z","phase":"Phase 3","brief_title":"Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™)","source_id_and_acronym":"NCT02013648","lead_sponsor":"University of Ulm","biomarkers":" RUNX1 • RUNX1T1","pipe":" | ","alterations":" RUNX1-RUNX1T1 fusion • CBFB-MYH11 fusion","tags":["RUNX1 • RUNX1T1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RUNX1-RUNX1T1 fusion • CBFB-MYH11 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • daunorubicin • idarubicin hydrochloride"],"overall_status":"Completed","enrollment":" Enrollment 204","initiation":"Initiation: 07/01/2014","start_date":" 07/01/2014","primary_txt":" Primary completion: 02/01/2024","primary_completion_date":" 02/01/2024","study_txt":" Completion: 02/01/2024","study_completion_date":" 02/01/2024","last_update_posted":"2024-02-23"},{"id":"95b055b1-d7c0-4581-b32f-575eb60dd1f0","acronym":"","url":"https://clinicaltrials.gov/study/NCT02283177","created_at":"2021-01-17T17:36:58.991Z","updated_at":"2024-07-02T16:35:21.166Z","phase":"Phase 2","brief_title":"A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations","source_id_and_acronym":"NCT02283177","lead_sponsor":"Arog Pharmaceuticals, Inc.","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • crenolanib (ARO-002) • daunorubicin • idarubicin hydrochloride"],"overall_status":"Completed","enrollment":" Enrollment 44","initiation":"Initiation: 01/01/2015","start_date":" 01/01/2015","primary_txt":" Primary completion: 12/01/2019","primary_completion_date":" 12/01/2019","study_txt":" Completion: 12/01/2019","study_completion_date":" 12/01/2019","last_update_posted":"2024-02-02"},{"id":"5263fd35-a4a0-4e33-9f9f-bb629d693c35","acronym":"","url":"https://clinicaltrials.gov/study/NCT06232694","created_at":"2024-02-01T02:21:09.039Z","updated_at":"2024-07-02T16:35:21.487Z","phase":"","brief_title":"Clinical Study Protocol of IAV-induced Remission Followed by Consolidation Therapy With MDCyta+Ven in ND-AML","source_id_and_acronym":"NCT06232694","lead_sponsor":"The First Affiliated Hospital with Nanjing Medical University","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • idarubicin hydrochloride"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 01/01/2024","start_date":" 01/01/2024","primary_txt":" Primary completion: 12/30/2027","primary_completion_date":" 12/30/2027","study_txt":" Completion: 12/30/2027","study_completion_date":" 12/30/2027","last_update_posted":"2024-01-31"},{"id":"df5b5086-1697-4c00-8ecc-c22d551b5706","acronym":"","url":"https://clinicaltrials.gov/study/NCT02339740","created_at":"2021-01-18T11:07:04.205Z","updated_at":"2024-07-02T16:35:28.404Z","phase":"Phase 3","brief_title":"Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia","source_id_and_acronym":"NCT02339740","lead_sponsor":"Children's Oncology Group","biomarkers":" FLT3 • RARA • PML","pipe":" | ","alterations":" FLT3 mutation • FLT3 wild-type","tags":["FLT3 • RARA • PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • FLT3 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • idarubicin hydrochloride • mitoxantrone • Vesanoid (tretinoin) • arsenic trioxide • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 158","initiation":"Initiation: 07/21/2015","start_date":" 07/21/2015","primary_txt":" Primary completion: 10/31/2020","primary_completion_date":" 10/31/2020","study_txt":" Completion: 09/22/2024","study_completion_date":" 09/22/2024","last_update_posted":"2023-11-22"},{"id":"c6a6748f-3901-4db0-9df8-1811b380e115","acronym":"QuANTUM-First","url":"https://clinicaltrials.gov/study/NCT02668653","created_at":"2021-01-18T13:00:34.703Z","updated_at":"2024-07-02T16:35:28.612Z","phase":"Phase 3","brief_title":"Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)","source_id_and_acronym":"NCT02668653 - QuANTUM-First","lead_sponsor":"Daiichi Sankyo, Inc.","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Vanflyta (quizartinib) • daunorubicin • idarubicin hydrochloride"],"overall_status":"Completed","enrollment":" Enrollment 539","initiation":"Initiation: 09/01/2016","start_date":" 09/01/2016","primary_txt":" Primary completion: 08/13/2021","primary_completion_date":" 08/13/2021","study_txt":" Completion: 06/16/2023","study_completion_date":" 06/16/2023","last_update_posted":"2023-11-20"},{"id":"d3fbe9fc-cb0c-4ea4-a0c8-0aaa88366b82","acronym":"TUD-APOLLO-064","url":"https://clinicaltrials.gov/study/NCT02688140","created_at":"2022-03-24T01:54:02.216Z","updated_at":"2024-07-02T16:35:30.678Z","phase":"Phase 3","brief_title":"Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia","source_id_and_acronym":"NCT02688140 - TUD-APOLLO-064","lead_sponsor":"Technische Universität Dresden","biomarkers":" PML","pipe":" | ","alterations":" PML-RARA fusion • Chr t(15;17) • Chr t(15;17)/PML-RARA fusion","tags":["PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PML-RARA fusion • Chr t(15;17) • Chr t(15;17)/PML-RARA fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • idarubicin hydrochloride • mitoxantrone • arsenic trioxide • mercaptopurine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 280","initiation":"Initiation: 06/01/2016","start_date":" 06/01/2016","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2023-11-02"},{"id":"b4ccd4e6-59d4-44c5-ac97-a4f7e703554d","acronym":"LAMSA2020","url":"https://clinicaltrials.gov/study/NCT04968015","created_at":"2021-07-20T14:52:24.830Z","updated_at":"2024-07-02T16:35:37.628Z","phase":"Phase 2","brief_title":"Venetoclax + Cytarabine Versus Idarubicin + Cytarabine : Efficacity Assessment as Post-remission Therapy to Elderly Patients With Acute Myeloid Leukemia in First Remission","source_id_and_acronym":"NCT04968015 - LAMSA2020","lead_sponsor":"French Innovative Leukemia Organisation","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • idarubicin hydrochloride"],"overall_status":"Recruiting","enrollment":" Enrollment 134","initiation":"Initiation: 05/25/2022","start_date":" 05/25/2022","primary_txt":" Primary completion: 08/15/2025","primary_completion_date":" 08/15/2025","study_txt":" Completion: 01/31/2029","study_completion_date":" 01/31/2029","last_update_posted":"2023-09-08"}]